We found that the time from transplantation to tumor initiation was delayed in tumor-bearing mice treated with either anti–PD-1 or anti–TIM-3 immunotherapy (Fig. 7 E), suggesting that the absence of γδ T cells unleashes checkpoint inhibitor-activated anti-tumor immunity in a model that is normally refractory to immunotherapy. This evidence concerns the gene HAVCR2 and neoplasm.